Research programme: viral RNA polymerase inhibitors - BioCryst

Drug Profile

Research programme: viral RNA polymerase inhibitors - BioCryst

Alternative Names: BCX-5191; BCX4678; Hepatitis C virus RNA polymerase inhibitors - BioCryst

Latest Information Update: 26 Feb 2013

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator BioCryst Pharmaceuticals; CNRS; Emory University
  • Developer BioCryst Pharmaceuticals
  • Class Nucleosides; Small molecules
  • Mechanism of Action DNA-directed RNA polymerase inhibitors; Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Ebola virus infections; Hepatitis C; West Nile virus infections

Most Recent Events

  • 31 Jan 2013 Discontinued - Preclinical for Hepatitis C in USA (PO)
  • 31 Jan 2013 BioCryst terminates preclinical trial in Hepatitis C virus infection in USA
  • 07 Dec 2012 BioCryst announces the company's strategic restructuring with focus on development of antiviral programmes, including BCX 5191 for HCV and a broad spectrum antiviral BCX 4430
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top